Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review

References

• BUIST AS. The US Lung Health Study. Respirology. 1997;2:303–307.
   PubMedGoogle Scholar
• Behrakis PKVC, Papadakis SE. eds. Tobacco cessation guidelines for high risk populations. 2017. Tob-G Project. accessed 2020 Nov 20; Available from: http://tob-g.eu/tobacco-cessation-guidelines-for-high-risk-populations-2/
   Google Scholar
• Tønnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013;22:37–43.
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Pulmonary Disease. 2019. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. accessed 2020 Sep.  Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.
   Google Scholar
• Nizet TA, van den Elshout FJ, Heijdra YF, et al. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest. 2005;(127):1904–1910.
   Google Scholar
• Gratziou C, Florou A, Ischaki E, et al. Smoking cessation effectiveness in smokers with COPD and asthma under real life conditions. Respir Med. 2014;108:577–583.
   PubMed Web of Science ®Google Scholar
• Jimenez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001;119:1365–1370.
   PubMed Web of Science ®Google Scholar
• Trofor AC, Man MA, Marginean C, et al. Smoking cessation for free: outcomes of a study of three Romanian clinics. Open Med (Wars). 2016;11:605–610.
   PubMedGoogle Scholar
• Trofor AC, Papadakis S, Lotrean L, et al. Tobacco treatment guideline for high risk groups: a pilot study in patients with chronic obstructive pulmonary disease. Tob Induc Dis. 2018;16:13.
   PubMed Web of Science ®Google Scholar
• Fiore MC. Treating tobacco use and dependence: an introduction to the US public health service clinical practice guideline. Respir Care. 2000;45:1196–1199.
   PubMedGoogle Scholar
• Fiore MC, Hatsukami DK, Baker TB. Effective tobacco dependence treatment. JAMA. 2002;(288):1768–1771.
   PubMed Web of Science ®Google Scholar
• Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;18(4):CD000165.
   PubMed Web of Science ®Google Scholar
• Fiore MCJC, Baker TB, et al. Treating tobacco use and dependence. Clinical practice guideline 2008 update. Rockville, MD, US: Department of Health and Human Services; 2008.
   Google Scholar
• Al SDe. American college of chest physicians tobacco-dependence treatment tool kit. 3rd Edition ed. 2010. Glenville, Illinois: American College of Chest Physician. Available from: https://foundation.chestnet.org/wp-content/uploads/2020/04/Tobacco-Dependence-Toolkit.pdf
   Google Scholar
• van Eerd EA, van der Meer RM, van Schayck OC, et al. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;2016(8):CD010744.
   PubMed Web of Science ®Google Scholar
• van Eerd EA, van Rossem CR, Spigt MG, et al. Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco smoking. Respiration. 2015;90:211–219.
   PubMed Web of Science ®Google Scholar
• The health consequences of smoking: nicotine addiction: a report of the Surgeon General. 1988. Available from: https://profiles.nlm.nih.gov/spotlight/nn/catalog/nlm:nlmuid-101584932X423-doc
   Google Scholar
• Hall SM, Herning RI, Jones RT, et al. Blood cotinine levels as indicators of smoking treatment outcome. Clin Pharmacol Ther. 1984;35:810–814.
   PubMed Web of Science ®Google Scholar
• Henningfield JE. Pharmacologic basis and treatment of cigarette smoking. J Clin Psychiatry. 1984;45:24–34.
   PubMed Web of Science ®Google Scholar
• Henningfield JE, Goldberg SR. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav. 1983;19:1021–1026.
   PubMed Web of Science ®Google Scholar
• Harvey DM, Yasar S, Heishman SJ, et al. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl). 2004;175:134–142.
   PubMed Web of Science ®Google Scholar
• Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;4(4):CD013308. doi:10.1002/14651858.CD013308.
   Web of Science ®Google Scholar
• Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89:392–399.
   PubMed Web of Science ®Google Scholar
• Shiffman S, Rolf CN, Hellebusch SJ, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002;97:505–516.
   PubMed Web of Science ®Google Scholar
• Wadgave U, Nagesh L. Nicotine replacement therapy: an overview. Int J Health Sci (Qassim). 2016;10:425–435.
   PubMedGoogle Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health study. JAMA. 1994;272:1497–1505.
   PubMed Web of Science ®Google Scholar
• Scanlon PD, Connett JE, Waller LA, et al. Lung health study research G. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The lung health study. Am J Respir Crit Care Med. 2000;161:381–390.
   PubMed Web of Science ®Google Scholar
• Murray RP, Gerald LB, Lindgren PG, et al. Characteristics of participants who stop smoking and sustain abstinence for 1 and 5 years in the lung health study. Prev Med. 2000;30:392–400.
   PubMed Web of Science ®Google Scholar
• Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. CHEST. 2006;130:334–342.
   PubMed Web of Science ®Google Scholar
• Lindson-Hawley N, Coleman T, Docherty G, et al. Nicotine patch preloading for smoking cessation (the preloading trial): study protocol for a randomized controlled trial. Trials. 2014;15:296.
   PubMedGoogle Scholar
• Preloading I. Effects on abstinence of nicotine patch treatment before quitting smoking: parallel, two arm, pragmatic randomised trial. BMJ. 2018;361:k2164–k2164.
   PubMedGoogle Scholar
• Przulj D, Wehbe L, McRobbie H, et al. Progressive nicotine patch dosing prior to quitting smoking: feasibility, safety and effects during the pre-quit and post-quit periods. Addiction. 2019;114:515–522.
   PubMed Web of Science ®Google Scholar
• Hartmann‐Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5(5):CD000146.
   PubMed Web of Science ®Google Scholar
• Haokip HR, Kumar DR, Singh Rawat DV, et al. Efficacy of standard nicotine replacement therapy (NRT) versus video-assisted nurse-led NRT on tobacco cessation: A randomized controlled pilot trial. Clin Epidemiol Global Health. 2020;9:141–146.
   Web of Science ®Google Scholar
• Wagena EJ, Arrindell WA, Wouters EF, et al. Are patients with COPD psychologically distressed? Eur Respir J. 2005;26:242–248.
   PubMed Web of Science ®Google Scholar
• Rigotti NA. Smoking cessation in patients with respiratory disease: existing treatments and future directions. Lancet Respir Med. 2013;1:241–250.
   PubMed Web of Science ®Google Scholar
• Strassmann R, Bausch B, Spaar A, et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009;34:634–640.
   PubMed Web of Science ®Google Scholar
• Jimenez-Ruiz CA, Fagerstrom KO. Smoking cessation treatment for COPD smokers: the role of pharmacological interventions. Monaldi Arch Chest Dis. 2013;79:27–32.
   PubMedGoogle Scholar
• Ellerbeck EF, Nollen N, Hutcheson TD, et al. Effect of long-term nicotine replacement therapy vs standard smoking cessation for smokers with chronic lung disease: a randomized clinical trial long-term nicotine replacement vs standard smoking cessation in chronic lung disease long-term nicotine replacement vs standard smoking cessation in chronic lung disease. JAMA Network Open. 2018;1:e181843–e181843.
   PubMed Web of Science ®Google Scholar
• Hagens P, Pieterse M, van der Valk P. Effectiveness of intensive smoking reduction counselling plus combination nicotine replacement therapy in promoting long-term abstinence in patients with chronic obstructive pulmonary disease not ready to quit smoking: protocol of the REDUQ trial. Contemp Clin Trials Commun. 2017;8:248–257.
   PubMed Web of Science ®Google Scholar
• Hashimoto R, Tomioka H, Wada T, et al. Outcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence. Respir Investig. 2020;58:387–394.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018;178:622–631.
   PubMed Web of Science ®Google Scholar
• Giulietti F, Filipponi A, Rosettani G, et al. Pharmacological approach to smoking cessation: an updated review for daily clinical practice. High Blood Press Cardiovasc Prev. 2020;27:349–362.
   PubMed Web of Science ®Google Scholar
• McClure JB, Swan GE, Catz SL, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat. 2010;38:394–402.
   PubMed Web of Science ®Google Scholar
• Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;2014(1):CD000031.
   PubMedGoogle Scholar
• Sterling LH, Windle SB, Filion KB, et al. Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;22;5(2):e002849. doi:10.1161/JAHA.115.002849
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline phase 3 study group ft. varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA. 2006;296:47–55.
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol. 2014;77:324–336.
   PubMed Web of Science ®Google Scholar
• Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial nicotine patch, varenicline, or combination therapy for smoking cessation nicotine patch, varenicline, or combination therapy for smoking cessation. JAMA. 2016;315:371–379.
   PubMed Web of Science ®Google Scholar
• Agboola SA, Coleman T, McNeill A, et al. Abstinence and relapse among smokers who use varenicline in a quit attempt—a pooled analysis of randomized controlled trials. Addiction. 2015;110:1182–1193.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139:591–599.
   PubMed Web of Science ®Google Scholar
• Jiménez-Ruiz CARPA, Cicero Guerrero A, Lopez Gonzalez G. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;14:1035–1039.
   PubMed Web of Science ®Google Scholar
• Sansores RH, Ramírez-Venegas A, Arellano-Rocha R, et al. Use of varenicline for more than 12 months for smoking cessation in heavy chronic obstructive pulmonary disease smokers unmotivated to quit: a pilot study. Ther Adv Respir Dis. 2016;10:383–390.
   PubMed Web of Science ®Google Scholar
• Hernández Zenteno RJ, Lara DF, Venegas AR, et al. Varenicline for long term smoking cessation in patients with COPD. Pulm Pharmacol Ther. 2018;53:116–120.
   PubMed Web of Science ®Google Scholar
• Politis A, Ioannidis V, Gourgoulianis KI, et al. Effects of varenicline therapy in combination with advanced behavioral support on smoking cessation and quality of life in inpatients with acute exacerbation of COPD, bronchial asthma, or community-acquired pneumonia: A prospective, open-label, preference-based, 52-week, follow-up trial. Chron Respir Dis. 2018;15:146–156.
   PubMed Web of Science ®Google Scholar
• Hilberink SR, Jacobs JE, Breteler MH, et al. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Educ Couns. 2011;83:120–124.
   PubMed Web of Science ®Google Scholar
• Tutka P, Vinnikov D, Courtney RJ, et al. Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction. 2019;114(11):1951–1969. doi:10.1111/add.14721. Epub 2019 Jul 19.
   Google Scholar
• Gómez-Coronado N, Walker AJ, Berk M, et al. Current and emerging pharmacotherapies for cessation of tobacco smoking. Pharmacotherapy. 2018;38:235–258.
   PubMed Web of Science ®Google Scholar
• Walker N, Howe C, Glover M, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med. 2014;371:2353–2362.
   PubMed Web of Science ®Google Scholar
• West R, Zatonski W, Cedzynska M, et al. Placebo-Controlled Trial of Cytisine for Smoking Cessation. N Engl J Med. 2011;365:1193–1200.
   PubMed Web of Science ®Google Scholar
• Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998;158:2035–2039.
   PubMedGoogle Scholar
• Herman AI, Sofuoglu M. Comparison of available treatments for tobacco addiction. Curr Psychiatry Rep. 2010;12:433–440.
   PubMed Web of Science ®Google Scholar
• Kotz D, Wesseling G, Huibers MJ, et al. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J. 2009;33:754–762.
   PubMed Web of Science ®Google Scholar
• Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;2004(3);CD000058.
   PubMed Web of Science ®Google Scholar
• Marlow SP, Stoller JK. Smoking Cessation. Respir Care. 2003;48:1238–1256.
   PubMedGoogle Scholar
• Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev. 2000;(4):CD002849.
   PubMedGoogle Scholar
• Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev. 2000;1998(2):CD001009.
   PubMedGoogle Scholar
• Nagano T, Katsurada M, Yasuda Y, et al. Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials. Ther Adv Respir Dis. 2019;13:1753466619875925.
   Web of Science ®Google Scholar
• Prado E, Maes M, Piccoli LG, et al. N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. Redox Rep. 2015;20:215–222.
   PubMed Web of Science ®Google Scholar
• Barua RS, Rigotti NA, Benowitz NL, et al. ACC expert consensus decision pathway on tobacco cessation treatment: a report of the american college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2018;72:3332–3365.
   PubMed Web of Science ®Google Scholar
• Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of E-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380:629–637.
   PubMed Web of Science ®Google Scholar
• Kyriakos CN, Filippidis FT, Hitchman S, et al. Consortium E-P. characteristics and correlates of electronic cigarette product attributes and undesirable events during e-cigarette use in six countries of the EUREST-PLUS ITC Europe surveys. Tob Induc Dis. 2018;16:A1–A1.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.
   PubMed Web of Science ®Google Scholar